Characterization of a human bispecific antibody against CD20/CD55 for the treatment of burkitt lymphoma

被引：0
|
作者：
Macor, Paolo [1 ]
Mezzaroba, Nelly [1 ]
De Maso, Luca [1 ]
Garrovo, Chiara [2 ]
Biffi, Stefania [2 ]
Sblattero, Daniele [3 ]
Marzari, Roberto [1 ]
Tedesco, Francesco [1 ]
机构：
[1] Univ Trieste, Dept Life Sci, Trieste, Italy
[2] CBM, Opt Imaging Lab, Trieste, Italy
[3] Univ Piemonte Orientale, Dept Med Sci, Novara, Italy
来源：
IMMUNOBIOLOGY | 2012年 / 217卷 / 11期
关键词：
D O I：
10.1016/j.imbio.2012.08.060
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
59
引用
收藏
页码：1149 / 1150
页数：2
相关论文
共 50 条
  • [21] A Recombinant Bispecific CD20 x CD95 Antibody With Superior Activity Against Normal and Malignant B-cells
    Nalivaiko, Kristina
    Hofmann, Martin
    Kober, Karina
    Teichweyde, Nadine
    Krammer, Peter H.
    Rammensee, Hans-Georg
    Grosse-Hovest, Ludger
    Jung, Gundram
    MOLECULAR THERAPY, 2016, 24 (02) : 298 - 305
  • [22] Production and Characterization of New Anti-Human CD20 Monoclonal Antibody
    Fasihi-Ramandi, Mahdi
    Amani, Jafar
    Salmanian, Ali-Hatef
    Moazzeni, Seyed Mohammad
    Ahmadi, Kazem
    IRANIAN JOURNAL OF ALLERGY ASTHMA AND IMMUNOLOGY, 2015, 14 (05) : 502 - 508
  • [23] Therapeutic potential of CD20/CD3 bispecific antibodies in the treatment of autoimmune diseases
    Huang, Hongpeng
    Wei, Xuetao
    RHEUMATOLOGY AND IMMUNOLOGY RESEARCH, 2025, 5 (04): : 209 - 216
  • [24] Antibody against CD20 in patients with B cell malignancy
    Adamson, PJ
    Zola, H
    Nicholson, IC
    Pilkington, G
    Hohmann, A
    LEUKEMIA RESEARCH, 2001, 25 (12) : 1047 - 1050
  • [25] The susceptibility of freshly isolated B-non Hodgkin lymphoma cells to Rituximab and complement is determined by CD20 levels and the CD55/CD59 inhibitors.
    Golay, J
    Lazzari, M
    Facchinetti, V
    Borleri, G
    Dastoli, G
    Barbui, T
    Introna, M
    Rambaldi, A
    BLOOD, 2000, 96 (11) : 338A - 338A
  • [26] Preparing Nurses for CD20-CD3 Bispecific Antibody Treatment in Patients With Non-Hodgkin Lymphoma
    van der Linde, Sam
    Knights, Emily
    Robertson, Molly
    Krishnasamy, Meinir
    Minson, Adrian
    Dickinson, Michael
    CANCER NURSING, 2024,
  • [27] An IgG1-like bispecific antibody targeting CD52 and CD20 for the treatment of B-cell malignancies
    Qi, Junpeng
    Chen, Shih-Shih
    Chiorazzi, Nicholas
    Rader, Christoph
    METHODS, 2019, 154 : 70 - 76
  • [28] CD20xCD3 Bispecific Fully Human Antibody Induces Potent Anti-Tumor Activity Against CD20-Expressing Tumors in Immune Competent Mice Humanized for CD20 and CD3
    Varghese, Bindu
    Menon, Jayanthi
    Rodriguez, Luis
    Olson, Kara
    Krueger, Pamela
    Huang, Tammy
    Smith, Eric
    Thurston, Gavin
    Kirshner, Jessica R.
    BLOOD, 2015, 126 (23)
  • [29] Recombinant bispecific monoclonal antibody (bsMAb) against CD20 and CD22 active in vitro and in vivo against B-cell lymphomas.
    Qu, Zhengxing
    Cardillo, Thomas M.
    Shi, Victoria
    Delaney, Diana L.
    Hansen, Hans J.
    Chang, Chien-Hsing
    Goldenberg, David M.
    BLOOD, 2006, 108 (11) : 713A - 714A
  • [30] Construction and Characterization of a Bispecific Anti-CD20 Antibody with Potent Antitumor Activity against B-Cell Lymphoma
    Li, Bohua
    Zhang, Xunming
    Shi, Shu
    Zhao, Lei
    Zhang, Dapeng
    Qian, Weizhu
    Zheng, Lei
    Gao, Jie
    Wang, Hao
    Guo, Yajun
    CANCER RESEARCH, 2010, 70 (15) : 6293 - 6302
12345